LAURA GETTLER: Open Payments
NPI 1114499654 · MISHAWAKA, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$450 in 21 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $14 · 2025 $450
Food & beverage: $431Education: $19
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $73 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Ardelyx, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
Products named: CAPLYTA, FANAPT, REXULTI, TRELEGY ELLIPTA, Auvelity, IBSRELA, GEMTESA, AIRSUPRA.
Industry payments across IN — which companies pay providers there.
